{"nctId":"NCT00781391","briefTitle":"Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation","startDateStruct":{"date":"2008-11"},"conditions":["Stroke","Atrial Fibrillation","Embolism"],"count":21105,"armGroups":[{"label":"Warfarin/placebo edoxaban","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: warfarin tablets","Drug: placebo edoxaban"]},{"label":"high dose edoxaban/placebo warfarin","type":"EXPERIMENTAL","interventionNames":["Drug: Edoxaban tablets (high dose regimen-60mg)","Drug: placebo warfarin"]},{"label":"low dose edoxaban/placebo warfarin","type":"EXPERIMENTAL","interventionNames":["Drug: Edoxaban tablets (low dose regimen-30mg)","Drug: placebo warfarin"]}],"interventions":[{"name":"warfarin tablets","otherNames":[]},{"name":"Edoxaban tablets (high dose regimen-60mg)","otherNames":[]},{"name":"Edoxaban tablets (low dose regimen-30mg)","otherNames":[]},{"name":"placebo warfarin","otherNames":[]},{"name":"placebo edoxaban","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 21 years of age or older; male or female.\n* Able to provide written informed consent.\n* History of documented AF within the prior 12 months\n* A moderate to high risk of stroke, as defined by CHADS2 index score of at least 2\n\nExclusion Criteria:\n\n* Transient atrial fibrillation secondary to other reversible disorders\n* Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve\n* Subjects with any contraindication for anticoagulant agents;\n* Subjects with conditions associated with high risk of bleeding or have known or suspected hereditary or acquired bleeding disorders\n* Females of childbearing potential including the following:\n\n  * Females with a history of tubal-ligation\n  * Females less than 2 years post-menopausal","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).","description":"The composite of stroke and Systemic Embolic Events (SEE) during the on treatment period in the mITT analysis population with a non-inferiority analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"182","spread":null},{"groupId":"OG002","value":"232","spread":null}]}]}]},{"type":"PRIMARY","title":"Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).","description":"The composite of stroke and Systemic Embolic Events (SEE) during the overall study period in the mITT analysis population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"382","spread":null},{"groupId":"OG001","value":"292","spread":null},{"groupId":"OG002","value":"336","spread":null}]}]}]},{"type":"PRIMARY","title":"Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).","description":"The composite of stroke and Systemic Embolic Events (SEE) during the on treatment period in the PP (per protocol) analysis set population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"182","spread":null},{"groupId":"OG002","value":"231","spread":null}]}]}]},{"type":"PRIMARY","title":"Compare Edoxaban to Warfarin for Composite of Stroke and Systemic Embolic Events (SEE).","description":"The composite of stroke and Systemic Embolic Events (SEE) during the overall study period in the PP (per protocol) analysis set population.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"382","spread":null},{"groupId":"OG001","value":"292","spread":null},{"groupId":"OG002","value":"335","spread":null}]}]}]},{"type":"PRIMARY","title":"Compare Edoxaban to Warfarin for Superiority for Composite of Stroke and Systemic Embolic Events (SEE).","description":"Compare edoxaban to warfarin for the composite of stroke and Systemic Embolic Events (SEE) during the overall study period in the ITT analysis set with a superiority analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"383","spread":null},{"groupId":"OG001","value":"296","spread":null},{"groupId":"OG002","value":"337","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Edoxaban to Warfarin for Composite of Stroke, Systemic Embolic Event (SEE), and Cardiovascular (CV) Mortality","description":"Compare edoxaban to warfarin for the composite of stroke, Systemic Embolic Events, and Cardiovascular mortality during the overall study period in the ITT analysis set.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"796","spread":null},{"groupId":"OG001","value":"728","spread":null},{"groupId":"OG002","value":"831","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Edoxaban to Warfarin for Major Adverse Cardiac Event (MACE): a Composite of Non-fatal MI, Non-fatal Stroke, Non-fatal SEE, and Death Due to CV Cause or Bleeding","description":"Compare edoxaban to warfarin for Major Adverse Cardiac Event (MACE): a composite of non-fatal Myocardial Infarction, non-fatal stroke, non-fatal Systemic Embolic Events, and death due to Cardiovascular cause or bleeding during the overall study period in the ITT analysis set.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"913","spread":null},{"groupId":"OG001","value":"827","spread":null},{"groupId":"OG002","value":"926","spread":null}]}]}]},{"type":"SECONDARY","title":"Compare Edoxaban to Warfarin for Composite of Stroke, SEE, and All-cause Mortality","description":"Compare Edoxaban to warfarin for Composite of stroke, Systemic Embolic Events, and all-cause mortality during the overall study period in the ITT analysis set.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"985","spread":null},{"groupId":"OG001","value":"949","spread":null},{"groupId":"OG002","value":"1046","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjudicated Bleeding Events","description":"Compare edoxaban versus warfarin for Adjudicated Bleeding Events during the on-treatment period in the Safety Analysis set.\n\nMajor bleeding was adjudicated by the Clinical Events Committee (CEC) and defined based on published guidance from the International Society on Thrombosis and Haemostasis (ISTH), with minor modifications for Hgb decrease and blood transfusion requirements.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"254","spread":null},{"groupId":"OG001","value":"418","spread":null},{"groupId":"OG002","value":"524","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"61","spread":null},{"groupId":"OG002","value":"132","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":null},{"groupId":"OG001","value":"359","spread":null},{"groupId":"OG002","value":"398","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"32","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"234","spread":null},{"groupId":"OG001","value":"386","spread":null},{"groupId":"OG002","value":"466","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"969","spread":null},{"groupId":"OG001","value":"1214","spread":null},{"groupId":"OG002","value":"1396","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1161","spread":null},{"groupId":"OG001","value":"1528","spread":null},{"groupId":"OG002","value":"1761","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"533","spread":null},{"groupId":"OG001","value":"604","spread":null},{"groupId":"OG002","value":"714","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1499","spread":null},{"groupId":"OG001","value":"1865","spread":null},{"groupId":"OG002","value":"2114","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3581,"n":7012},"commonTop":["urinary tract infection","nasopharyngitis","oedema peripheral","bronchitis","dizziness"]}}}